Carter Keller, Co-Founder of GigaMune, Co-Founder and Head of GigaGen, shared Grifols‘ post on LinkedIn, adding:
“I am excited to attend AACR this year and help introduce the world to GIGA-564’s initial clinical data. As the only non-blocking CTLA4 mAb in development the data will show what targeting T regulatory cells in the tumor environment can mean for patients.
If you are going to the conference please reach out to meet, catch up or discuss the data.
See you in San Diego.”
Quoting Grifols‘ post:
“GigaGen, a subsidiary of Grifols, will present clinical data for GIGA-564 for the first time at the AACR Annual Meeting 2026, one of the leading global forums in oncology research.
The poster will share preliminary results from a first-in-human Phase 1 study of GIGA-564, a non-blocking anti-CTLA–4 antibody designed to deplete intratumoral regulatory T cells (Tregs) in patients with advanced or metastatic solid tumors.
The study will be presented by James Gully, MD, PhD, from the National Cancer Institute.
- April 20, 2026
- 2:00 PM (PT)
- San Diego, U.S.
Other articles on OncoDaily.